Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Topical YJ001 in Healthy Volunteers
NCT05451667Phase 1Completed
- Sponsor
- Yuejia Pharmaceuticals
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YJ001 in diabetic polyneuropathy (DPN) (5 arms), sponsored by Yuejia Pharmaceuticals. Primary endpoints: Incidence of adverse events and significant laboratory abnormality and Systemic exposure of the 4 analytes to be assayed. Started Aug 2022; status: completed.
02
Drugs
YJ001
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT05451667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451667.